Consolidated Financial Results for the Six Months ended September 30, 2026 (FY2026) (Japanese standard)10/29 15:30TDnetPDF(551KB)
Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for JR-141 in the United States, Europe, and Latin America10/2 15:30TDnetPDF(226KB)
Consolidated Financial Results for the Three Months ended June 30, 2026 (FY2026) (Japanese standard)7/30 15:30TDnetPDF(362KB)
Notice Regarding the Completion of Payment for the Disposition of Treasury Stock as Restricted Stock Compensation7/22 16:00TDnetPDF(227KB)
JCR Pharmaceuticals Announces Development Plan in Japan for Givinostat for Duchenne Muscular Dystrophy7/15 8:30TDnetPDF(205KB)
Partial Correction: Consolidated Financial Results for the Full Year ended March 31, 2026 (FY2025)(Japanese standard) 6/23 16:00TDnetPDF(641KB)
Partial Correction: Consolidated Financial Results for the Full Year ended March 31, 2025 (FY2024)(Japanese standard) 6/23 16:00TDnetPDF(529KB)